A multicenter study led by UC Davis Health has tested a new treatment designed to improve care for people with a rare liver ...
USA: A large retrospective, propensity score–matched cohort study found that ursodeoxycholic acid (UDCA) use in patients with ...
Phase II ELMWOOD trial shows elafibranor is well tolerated and improves liver biochemistry and pruritus in primary sclerosing ...
MedPage Today on MSN
Liver Disease Medication Linked to Lower Cancer Risks
Using electronic health record data from more than 12,000 PBC patients, investigators found that UDCA use was associated with ...
Discover why Mirum Pharmaceuticals, Inc. stock surged 65%. Explore robust pipeline growth, revenue outlook, and analyst ...
Mirum's Livmarli sales surge 70% in the first nine months of 2025. Expanding approvals and commercialization are set to fuel revenue momentum into 2026.
The firings come one month after the company voluntarily pulled a drug from the market at the request of the Food and Drug ...
(Nasdaq: MIRM), a leading rare disease company, today announced that it has entered into a subscription agreement with ...
TipRanks on MSN
Mirum Pharmaceuticals raises capital via private placement
Mirum Pharmaceuticals ( ($MIRM) ) just unveiled an announcement. On December 18, 2025, Mirum Pharmaceuticals entered into a subscription agreement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback